{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T05:08:31Z","timestamp":1783573711820,"version":"3.55.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,11,8]],"date-time":"2018-11-08T00:00:00Z","timestamp":1541635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Oncoral Pharma"},{"DOI":"10.13039\/100012774","name":"Innovationsfonden","doi-asserted-by":"publisher","award":["5184-00055B"],"award-info":[{"award-number":["5184-00055B"]}],"id":[{"id":"10.13039\/100012774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008363","name":"Kr\u00e6ftens Bek\u00e6mpelse","doi-asserted-by":"publisher","award":["R110-A7013"],"award-info":[{"award-number":["R110-A7013"]}],"id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1007\/s00280-018-3720-7","type":"journal-article","created":{"date-parts":[[2018,11,8]],"date-time":"2018-11-08T07:32:54Z","timestamp":1541662374000},"page":"169-178","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Oral administration of irinotecan in patients with solid tumors: an open-label, phase I, dose escalating study evaluating safety, tolerability and pharmacokinetics"],"prefix":"10.1007","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5082-3660","authenticated-orcid":false,"given":"I.","family":"K\u00fcmler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Grundtvig","family":"S\u00f8rensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Palshof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"H\u00f8gdall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Skovrider-Ruminski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Theile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Fullerton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. G.","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. Vittrup","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. L.","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,8]]},"reference":[{"issue":"Suppl 3","key":"3720_CR1","doi-asserted-by":"publisher","first-page":"iii1","DOI":"10.1093\/annonc\/mdu260","volume":"25","author":"E Cutsem Van","year":"2014","unstructured":"Van Cutsem E, Cervantes A, Nordlinger B, Arnold D, Group EGW (2014) Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 25(Suppl 3):iii1\u2013i9. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdu260","journal-title":"Ann Oncol"},{"key":"3720_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-018-0644-7","author":"FM Man de","year":"2018","unstructured":"de Man FM, Goey AKL, van Schaik RHN, Mathijssen RHJ, Bins S (2018) Individualization of irinotecan treatment: a review of pharmacokinetics, pharmacodynamics, and pharmacogenetics. Clin Pharmacokinet. \n                    https:\/\/doi.org\/10.1007\/s40262-018-0644-7","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"3720_CR3","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1093\/oxfordjournals.annonc.a059107","volume":"6","author":"DJ Wagener","year":"1995","unstructured":"Wagener DJ, Verdonk HE, Dirix LY, Catimel G, Siegenthaler P, Buitenhuis M, Mathieu-Boue A, Verweij J (1995) Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study. Ann Oncol 6(2):129\u2013132","journal-title":"Ann Oncol"},{"issue":"4","key":"3720_CR4","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s00280-006-0283-9","volume":"59","author":"H Ueno","year":"2007","unstructured":"Ueno H, Okusaka T, Funakoshi A, Ishii H, Yamao K, Ishikawa O, Ohkawa S, Saitoh S (2007) A phase II study of weekly irinotecan as first-line therapy for patients with metastatic pancreatic cancer. Cancer Chemother Pharmacol 59(4):447\u2013454. \n                    https:\/\/doi.org\/10.1007\/s00280-006-0283-9","journal-title":"Cancer Chemother Pharmacol"},{"issue":"19","key":"3720_CR5","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardiere C, Bennouna J, Bachet JB, Khemissa-Akouz F, Pere-Verge D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M, Groupe Tumeurs Digestives of Unicancer and the PRODIGE Intergroup (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364(19):1817\u20131825. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1011923","journal-title":"N Engl J Med"},{"issue":"15","key":"3720_CR6","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1016\/j.ejca.2011.06.002","volume":"47","author":"PC Thuss-Patience","year":"2011","unstructured":"Thuss-Patience PC, Kretzschmar A, Bichev D, Deist T, Hinke A, Breithaupt K, Dogan Y, Gebauer B, Schumacher G, Reichardt P (2011) Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer\u2014a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer 47(15):2306\u20132314. \n                    https:\/\/doi.org\/10.1016\/j.ejca.2011.06.002","journal-title":"Eur J Cancer"},{"issue":"6","key":"3720_CR7","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1093\/annonc\/mdt002","volume":"24","author":"AC Roy","year":"2013","unstructured":"Roy AC, Park SR, Cunningham D, Kang YK, Chao Y, Chen LT, Rees C, Lim HY, Tabernero J, Ramos FJ, Kujundzic M, Cardic MB, Yeh CG, de Gramont A (2013) A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma. Ann Oncol 24(6):1567\u20131573. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdt002","journal-title":"Ann Oncol"},{"issue":"2","key":"3720_CR8","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1200\/JCO.1999.17.2.685","volume":"17","author":"RL Drengler","year":"1999","unstructured":"Drengler RL, Kuhn JG, Schaaf LJ, Rodriguez GI, Villalona-Calero MA, Hammond LA, Stephenson JA Jr, Hodges S, Kraynak MA, Staton BA, Elfring GL, Locker PK, Miller LL, Von Hoff DD, Rothenberg ML (1999) Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors. J Clin Oncol 17(2):685\u2013696","journal-title":"J Clin Oncol"},{"issue":"2","key":"3720_CR9","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s00280-005-0138-9","volume":"58","author":"HC Pitot","year":"2006","unstructured":"Pitot HC, Adjei AA, Reid JM, Sloan JA, Atherton PJ, Rubin J, Alberts SR, Duncan BA, Denis L, Schaaf LJ, Yin D, Sharma A, McGovren P, Miller LL, Erlichman C (2006) A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumors. Cancer Chemother Pharmacol 58(2):165\u2013172. \n                    https:\/\/doi.org\/10.1007\/s00280-005-0138-9","journal-title":"Cancer Chemother Pharmacol"},{"issue":"8 Suppl 6","key":"3720_CR10","first-page":"68","volume":"12","author":"ML Rothenberg","year":"1998","unstructured":"Rothenberg ML, Kuhn JG, Schaaf LJ, Drengler RL, Eckhardt SG, Villalona-Calero MA, Hammond L, Miller LL, Petit RG, Rowinsky EK, Von Hoff DD (1998) Alternative dosing schedules for irinotecan. Oncology (Williston Park) 12(8 Suppl 6):68\u201371","journal-title":"Oncology (Williston Park)"},{"issue":"3","key":"3720_CR11","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.hoc.2012.03.002","volume":"26","author":"J Moukharskaya","year":"2012","unstructured":"Moukharskaya J, Verschraegen C (2012) Topoisomerase 1 inhibitors and cancer therapy. Hematol Oncol Clin N Am 26(3):507\u2013525. \n                    https:\/\/doi.org\/10.1016\/j.hoc.2012.03.002\n                    \n                   vii.","journal-title":"Hematol Oncol Clin N Am"},{"issue":"1","key":"3720_CR12","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jconrel.2013.07.022","volume":"172","author":"V Bala","year":"2013","unstructured":"Bala V, Rao S, Boyd BJ, Prestidge CA (2013) Prodrug and nanomedicine approaches for the delivery of the camptothecin analogue SN38. J Control Release 172(1):48\u201361. \n                    https:\/\/doi.org\/10.1016\/j.jconrel.2013.07.022","journal-title":"J Control Release"},{"issue":"1","key":"3720_CR13","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1021\/acs.molpharmaceut.5b00785","volume":"13","author":"V Bala","year":"2016","unstructured":"Bala V, Rao S, Li P, Wang S, Prestidge CA (2016) Lipophilic prodrugs of SN38: synthesis and in vitro characterization toward oral chemotherapy. Mol Pharm 13(1):287\u2013294. \n                    https:\/\/doi.org\/10.1021\/acs.molpharmaceut.5b00785","journal-title":"Mol Pharm"},{"key":"3720_CR14","first-page":"130","volume":"22","author":"J Berlin","year":"2003","unstructured":"Berlin J, Benson AB, Rubin EH et al (2003) Phase I safety, pharmacokinetic and bioavailability study of a semi-solid matrix formulations of oral irinotecan in patients with advanced solid tumors. Proc Am Soc Clin Oncol 22:130 (Abstract 521)","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"7","key":"3720_CR15","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1093\/annonc\/mdl071","volume":"17","author":"H Dumez","year":"2006","unstructured":"Dumez H, Awada A, Piccart M, Assadourian S, Semiond D, Guetens G, de Boeck G, Maes RA, de Bruijn EA, van Oosterom A (2006) A phase I dose-finding clinical pharmacokinetic study of an oral formulation of irinotecan (CPT-11) administered for 5 days every 3 weeks in patients with advanced solid tumours. Ann Oncol 17(7):1158\u20131165. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdl071","journal-title":"Ann Oncol"},{"issue":"1","key":"3720_CR16","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1007\/s10637-010-9528-x","volume":"30","author":"LW Goff","year":"2012","unstructured":"Goff LW, Benson AB III, LoRusso PM, Tan AR, Berlin JD, Denis LJ, Benner RJ, Yin D, Rothenberg ML (2012) Phase I study of oral irinotecan as a single-agent and given sequentially with capecitabine. Investig New Drugs 30(1):290\u2013298. \n                    https:\/\/doi.org\/10.1007\/s10637-010-9528-x","journal-title":"Investig New Drugs"},{"issue":"12","key":"3720_CR17","doi-asserted-by":"publisher","first-page":"3774","DOI":"10.1158\/1078-0432.CCR-05-2368","volume":"12","author":"IE Kuppens","year":"2006","unstructured":"Kuppens IE, Dansin E, Boot H, Feger C, Assadourian S, Bonneterre ME, Beijnen JH, Schellens JH, Bonneterre J (2006) Dose-finding phase I clinical and pharmacokinetic study of orally administered irinotecan in patients with advanced solid tumors. Clin Cancer Res 12(12):3774\u20133781. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-05-2368","journal-title":"Clin Cancer Res"},{"issue":"3","key":"3720_CR18","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s00280-004-0874-2","volume":"55","author":"NE Schoemaker","year":"2005","unstructured":"Schoemaker NE, Kuppens IE, Huinink WW, Lefebvre P, Beijnen JH, Assadourian S, Sanderink GJ, Schellens JH (2005) Phase I study of an oral formulation of irinotecan administered daily for 14 days every 3 weeks in patients with advanced solid tumours. Cancer Chemother Pharmacol 55(3):263\u2013270. \n                    https:\/\/doi.org\/10.1007\/s00280-004-0874-2","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"3720_CR19","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1158\/1078-0432.CCR-04-1758","volume":"11","author":"O Soepenberg","year":"2005","unstructured":"Soepenberg O, Dumez H, Verweij J, de Jong FA, de Jonge MJ, Thomas J, Eskens FA, van Schaik RH, Selleslach J, Ter Steeg J, Lefebvre P, Assadourian S, Sanderink GJ, Sparreboom A, van Oosterom AT (2005) Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors. Clin Cancer Res 11(4):1504\u20131511. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-04-1758","journal-title":"Clin Cancer Res"},{"issue":"16","key":"3720_CR20","doi-asserted-by":"publisher","first-page":"3387","DOI":"10.1016\/j.ejca.2013.06.038","volume":"49","author":"K Lien","year":"2013","unstructured":"Lien K, Georgsdottir S, Sivanathan L, Chan K, Emmenegger U (2013) Low-dose metronomic chemotherapy: a systematic literature analysis. Eur J Cancer 49(16):3387\u20133395. \n                    https:\/\/doi.org\/10.1016\/j.ejca.2013.06.038","journal-title":"Eur J Cancer"},{"issue":"1","key":"3720_CR21","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ejpb.2011.01.021","volume":"79","author":"E Roger","year":"2011","unstructured":"Roger E, Lagarce F, Benoit JP (2011) Development and characterization of a novel lipid nanocapsule formulation of Sn38 for oral administration. Eur J Pharm Biopharm 79(1):181\u2013188. \n                    https:\/\/doi.org\/10.1016\/j.ejpb.2011.01.021","journal-title":"Eur J Pharm Biopharm"},{"issue":"3","key":"3720_CR22","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.jconrel.2010.11.022","volume":"150","author":"DS Goldberg","year":"2011","unstructured":"Goldberg DS, Vijayalakshmi N, Swaan PW, Ghandehari H (2011) G3.5 PAMAM dendrimers enhance transepithelial transport of SN38 while minimizing gastrointestinal toxicity. J Control Release 150(3):318\u2013325. \n                    https:\/\/doi.org\/10.1016\/j.jconrel.2010.11.022","journal-title":"J Control Release"},{"issue":"Suppl12","key":"3720_CR23","doi-asserted-by":"publisher","first-page":"C218","DOI":"10.1158\/1535-7163","volume":"8","author":"D Garrec Le","year":"2009","unstructured":"Le Garrec D, Benquet C, Lessard D, Parisien M, Palusova D, Kujawa P, Baille W, Nasser-Eddine M, Smith D (2009) Antitumor activities of a novel oral formulation of SN38. Mol Cancer Ther 8(Suppl12):C218. \n                    https:\/\/doi.org\/10.1158\/1535-7163\n                    \n                  . TARG-09-C218","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"3720_CR24","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228\u2013247. \n                    https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"issue":"10","key":"3720_CR25","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1097\/CAD.0b013e328330c7d2","volume":"20","author":"C Schulz","year":"2009","unstructured":"Schulz C, Boeck S, Heinemann V, Stemmler HJ (2009) UGT1A1 genotyping: a predictor of irinotecan-associated side effects and drug efficacy? Anticancer Drugs 20(10):867\u2013879. \n                    https:\/\/doi.org\/10.1097\/CAD.0b013e328330c7d2","journal-title":"Anticancer Drugs"},{"key":"3720_CR26","unstructured":"FDA (2009) FDA highlight of prescribing information for Camptosar injection, intravenous infusion. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/020571s031s032s033s036s037lbl.pdf\n                    \n                  . Accessed 8 Nov 2018"},{"key":"3720_CR27","unstructured":"Inc PC (2018) Product Monograph for irinotecan hydrochloride trihydrate for injection 20 mg\/mL. \n                    https:\/\/www.pfizerca\/sites\/g\/files\/g10045006\/f\/201803\/20181313_Irinotecan_PM_E_212772.pdf"},{"issue":"6","key":"3720_CR28","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5(6):649\u2013655","journal-title":"Am J Clin Oncol"},{"key":"3720_CR29","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.28.15_suppl.e14109","author":"V Moiseyenko","year":"2010","unstructured":"Moiseyenko V, Chubenko V, Protsenko S (2010) Phase II study of metronomic chemotherapy with irinotecan in patients with refractory metastatic colorectal cancer. J Clin Oncol. \n                    https:\/\/doi.org\/10.1200\/jco.2010.28.15_suppl.e14109","journal-title":"J Clin Oncol"},{"issue":"14","key":"3720_CR30","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1200\/JCO.2004.10.047","volume":"22","author":"EA Perez","year":"2004","unstructured":"Perez EA, Hillman DW, Mailliard JA, Ingle JN, Ryan JM, Fitch TR, Rowland KM, Kardinal CG, Krook JE, Kugler JW, Dakhil SR (2004) Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both. J Clin Oncol 22(14):2849\u20132855. \n                    https:\/\/doi.org\/10.1200\/JCO.2004.10.047","journal-title":"J Clin Oncol"},{"issue":"8","key":"3720_CR31","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1038\/sj.bjc.6604311","volume":"98","author":"G Allegrini","year":"2008","unstructured":"Allegrini G, Falcone A, Fioravanti A, Barletta MT, Orlandi P, Loupakis F, Cerri E, Masi G, Di Paolo A, Kerbel RS, Danesi R, Del Tacca M, Bocci G (2008) A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients. Br J Cancer 98(8):1312\u20131319. \n                    https:\/\/doi.org\/10.1038\/sj.bjc.6604311","journal-title":"Br J Cancer"},{"issue":"1","key":"3720_CR32","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1177\/1758834009355164","volume":"2","author":"A Stein","year":"2010","unstructured":"Stein A, Voigt W, Jordan K (2010) Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. Ther Adv Med Oncol 2(1):51\u201363. \n                    https:\/\/doi.org\/10.1177\/1758834009355164","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"3720_CR33","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/sj.tpj.6500072","volume":"2","author":"L Iyer","year":"2002","unstructured":"Iyer L, Das S, Janisch L, Wen M, Ramirez J, Karrison T, Fleming GF, Vokes EE, Schilsky RL, Ratain MJ (2002) UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2(1):43\u201347","journal-title":"Pharmacogenomics J"},{"issue":"4","key":"3720_CR34","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1200\/JCO.1996.14.4.1128","volume":"14","author":"ML Rothenberg","year":"1996","unstructured":"Rothenberg ML, Eckardt JR, Kuhn JG, Burris HA III, Nelson J, Hilsenbeck SG, Rodriguez GI, Thurman AM, Smith LS, Eckhardt SG, Weiss GR, Elfring GL, Rinaldi DA, Schaaf LJ, Von Hoff DD (1996) Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 14(4):1128\u20131135. \n                    https:\/\/doi.org\/10.1200\/JCO.1996.14.4.1128","journal-title":"J Clin Oncol"},{"issue":"2","key":"3720_CR35","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1200\/JCO.1997.15.2.625","volume":"15","author":"CF Verschraegen","year":"1997","unstructured":"Verschraegen CF, Levy T, Kudelka AP, Llerena E, Ende K, Freedman RS, Edwards CL, Hord M, Steger M, Kaplan AL, Kieback D, Fishman A, Kavanagh JJ (1997) Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix. J Clin Oncol 15(2):625\u2013631. \n                    https:\/\/doi.org\/10.1200\/JCO.1997.15.2.625","journal-title":"J Clin Oncol"},{"issue":"4","key":"3720_CR36","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1023\/A:1026207519884","volume":"21","author":"R Sanchez","year":"2003","unstructured":"Sanchez R, Esteban E, Palacio I, Fernandez Y, Muniz I, Vieitez JM, Fra J, Blay P, Villanueva N, Una E, Mareque B, Estrada E, Buesa JM, Lacave AJ (2003) Activity of weekly irinotecan (CPT-11) in patients with advanced non-small cell lung cancer pretreated with platinum and taxanes. Investig New Drugs 21(4):459\u2013463","journal-title":"Investig New Drugs"},{"issue":"8","key":"3720_CR37","doi-asserted-by":"publisher","first-page":"2910","DOI":"10.1200\/JCO.1997.15.8.2910","volume":"15","author":"HC Pitot","year":"1997","unstructured":"Pitot HC, Wender DB, O\u2019Connell MJ, Schroeder G, Goldberg RM, Rubin J, Mailliard JA, Knost JA, Ghosh C, Kirschling RJ, Levitt R, Windschitl HE (1997) Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol 15(8):2910\u20132919. \n                    https:\/\/doi.org\/10.1200\/JCO.1997.15.8.2910","journal-title":"J Clin Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-018-3720-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-018-3720-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-018-3720-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,7]],"date-time":"2019-11-07T19:11:19Z","timestamp":1573153879000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-018-3720-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,8]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["3720"],"URL":"https:\/\/doi.org\/10.1007\/s00280-018-3720-7","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,8]]},"assertion":[{"value":"20 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The study was initiated by the primary investigator at the Department of Oncology, Herlev and Gentofte Hospital. All study medication was manufactured and provided by Oncoral Pharma ApS. The study was partly funded by grants from Innovationsfonden (Innovation Fund Denmark) and the Danish Cancer Society. Oncoral Pharma is partly owned by Peter G Nielsen and Ann Fullerton. All other authors declare no conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}